
(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |
---|---|---|---|---|---|---|---|
3fw1 | STI | Imatinib (DB00619) | Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. | RIBOSYLDIHYDRONICOTINAMIDE DEHYDROGENASE [QUINONE] (Homo sapiens) | Flavodoxin_2 | ||
3owx | XRA | Prazosin (DB00457) | Prazosin is an alpha-blocker that causes a decrease in total peripheral resistance and is used to treat hypertension. | RIBOSYLDIHYDRONICOTINAMIDE DEHYDROGENASE [QUINONE] (Homo sapiens) | Flavodoxin_2 | ||
4fgj | 1PQ | Primaquine (DB01087) | Primaquine is an antimalarial indicated to prevent relapse of vivax malaria. | RIBOSYLDIHYDRONICOTINAMIDE DEHYDROGENASE [QUINONE] (Homo sapiens) | Flavodoxin_2 | ||
4fgl | CLQ | Chloroquine (DB00608) | Chloroquine is an antimalarial drug used to treat susceptible infections with P. vivax, P. malariae, P. ovale, and P. falciparum. It is also used for second line treatment for rheumatoid arthritis. | RIBOSYLDIHYDRONICOTINAMIDE DEHYDROGENASE [QUINONE] (Homo sapiens) | Flavodoxin_2 | ||
4zvm | DM2 | Doxorubicin (DB00997) | Doxorubicin is a medication used to treat various cancers and Kaposi's Sarcoma. | RIBOSYLDIHYDRONICOTINAMIDE DEHYDROGENASE [QUINONE] (Homo sapiens) | Flavodoxin_2 | ||
5lbt | 6T0 | Imiquimod (DB00724) | Imiquimod is a toll-like receptor 7 agonist used to treat non hyperkeratotic, non hypertrophic actinic keratosis, basal cell carcinoma, genital or perianal warts, and condyloma acuminata. | RIBOSYLDIHYDRONICOTINAMIDE DEHYDROGENASE [QUINONE] (Homo sapiens) | Flavodoxin_2 | ||
PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |